BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema. The company’s chief business officer
MarketBeat ·
MarketBeat
